Comparative Pharmacology
Head-to-head clinical analysis: ADPHEN versus FENFLURAMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADPHEN versus FENFLURAMINE.
ADPHEN vs FENFLURAMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adphen is a combination of phentermine hydrochloride and diethylpropion hydrochloride. Phentermine is a sympathomimetic amine that acts as an appetite suppressant by stimulating the hypothalamus to release norepinephrine, thereby reducing food intake. Diethylpropion also has sympathomimetic activity, though its exact mechanism is not fully understood.
Fenfluramine is a serotonin-releasing agent and serotonin receptor agonist. It increases extracellular serotonin levels by promoting release from presynaptic neurons and inhibiting reuptake, leading to appetite suppression. Its antiseizure effect in Dravet syndrome is thought to be mediated via 5-HT2 receptor activation, enhancing inhibitory neurotransmission.
5 mg orally once daily, titrated to a maximum of 10 mg once daily as tolerated.
25 mg orally three times daily, titrated to a maximum of 400 mg daily in divided doses.
None Documented
None Documented
Clinical Note
moderateDexfenfluramine + Deferasirox
"The serum concentration of Deferasirox can be increased when it is combined with Dexfenfluramine."
Clinical Note
moderateDexfenfluramine + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Dexfenfluramine."
Clinical Note
moderateDexfenfluramine + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Dexfenfluramine."
Clinical Note
moderateDexfenfluramine + Artesunate
Terminal elimination half-life is 10-15 hours in adults with normal renal function; prolonged to 20-30 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life of fenfluramine is approximately 20 hours (range 13–30 hours) for the parent drug, while its active metabolite norfenfluramine has a longer half-life of approximately 30–34 hours. This extended half-life supports twice-daily dosing but contributes to accumulation with repeated administration.
Primarily renal (70-90% as unchanged drug) with minor biliary (10-15% as metabolites). Fecal elimination is negligible (<5%).
Renal excretion of unchanged drug accounts for <1% of the administered dose; fenfluramine is extensively metabolized, with metabolites primarily excreted renally. Approximately 60–70% of the dose appears in urine as metabolites (including norfenfluramine and other dealkylated products) within 72 hours, and about 5–10% is eliminated in feces via biliary excretion.
Category C
Category C
Anorexiant
Anorexiant
"The serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Dexfenfluramine resulting in a loss in efficacy."